PEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO

PEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO